替吉奥及多西他赛联合奈达铂治疗中晚期食管癌的临床研究

Clinical observation of S-1 or docetaxel combined with nedaplatin in the moderate and advanced stages of esophageal cancer

目的：探讨替吉奥＋奈达铂、多西他赛＋奈达铂方案加同步放疗治疗中晚期食管癌的疗效及不良反应。方法56例中晚期食管癌患者随机分为替吉奥＋奈达铂组28例和多西他赛＋奈达铂28例。两组患者放疗均与化疗同步。结果替吉奥＋奈达铂、多西他赛＋奈达铂组有效率分别为82.1%、85.7%，两组比较差异无统计学意义（P 〉0.05）。主要不良反应为消化道反应、骨髓抑制、放射性气管炎、放射性食管炎、静脉炎。多西他赛＋奈达铂组骨髓抑制较重，两组间比较差异有统计学意义（P 〈0.05）。经对症处理后患者可以耐受，无治疗相关性死亡。结论两方案同步放化疗治疗均可用于中晚期食管癌的综合治疗，替吉奥＋奈达铂组毒不良反应轻。

Objective To investigate the efficacy and safety of S-1 combined with nedaplatin,do-cetaxel combined with nedaplatin plus concurrent radiotherapy in the treatment of moderate and advanced stages of esophageal cancer. Methods Fifty-six patients with the moderate and advanced stages of esopha-geal cancer were randomly divided into two groups：S-1 combined with nedaplatin,docetaxel combined with nedaplatin plus concurrent radiotherapy. Results The effective rate in the S-1 combined with nedapl-atin group and the docetaxel combined with nedaplatin group was 82. 1% and 85. 7%,the difference was not statistically significant. The main side effects were gastrointestinal reactions,myelosuppression,radio-active bronchitis,radioactive esophagitis,phlebitis. Docetaxel combined with nedaplatin had more the heavier myelosuppression,but it could be controlled after treatment. Conclusions Two concurrent chemo-radiation therapy program can be used. S-1 combined with nedaplatin has light toxic effects.